ipopba - stock.adobe.com
Pfizer Appoints David M. Denton as CFO, Executive Vice President
As Moderna's CFO, Denton will be a key thought partner to the company's CEO and executive leadership team and be responsible for all corporate finance functions.
Pfizer recently announced that David M. Denton will replace Frank D'Amelio as chief financial officer (CFO) and executive vice president of the company.
Before Pfizer, Denton served as executive vice president and CFO of CVS Health and was responsible for all aspects of their financial planning and management. He also led the full integration of Caremark into CVS and was a crucial member in CVS' acquisition of Aetna.
Later in his career, Denton was the CFO and executive vice president of Lowe's Companies where he gained over 25 years of finance and operational expertise, including more than 20 years in the healthcare sector.
As CFO and executive vice president of Pfizer, Denton will be a key thought partner to the company's CEO and executive leadership team. He will also oversee all corporate finance functions, including audit, treasury, tax, insurance, operations planning and analysis (OP&A), corporate controllership, and business finance and analytics.
Denton will take this position in May 2022 and report to Pfizer chairman and chief executive officer (CEO), Albert Bourla.
"Our Company's continued financial strength is essential to Pfizer's ability to deliver on our purpose and to create long-term value for all our stakeholders," Bourla said in the recent announcement.
"Dave brings with him deep financial experience, a track record of achievement, and true insights into today's healthcare system. For these reasons, he is the perfect leader to take the helm of our talented finance organization and deliver a comprehensive strategic financial vision that will help drive Pfizer's future growth and success," he continued.
And Denton emphasized that there could be no professional opportunity greater than leveraging all of his years of finance and business experience to work alongside a high-performing team built for growth and enhancing shareholder returns.
Jorge Gomez Joins Moderna as CFO
Moderna recently announced that Jorge Gomez will replace David Meline as the company's CFO, effective May 2022.
Gomez joins Moderna from Dentsply Sirona, where he served as executive vice president and CFO from August 2019 to 2022. During his time at the company, Gomez led strategic finance, FP&A, accounting, treasury, tax, corporate audit and investor relations, and the information technology function. He also led the sustainability and ESG program.
Prior to his position at Dentsply Sirona, Gomez was the medical segment CFO, pharmaceutical segment CFO, corporate treasurer, and corporate controller of Cardinal Health over a 13 year period.
As CFO of Moderna, Gomez will serve on the company's executive committee and report to chief executive officer Stéphane Bancel.
"As we grow and scale the company globally, Jorge's experience leading the financial functions of multinational healthcare companies will be an asset to our team. Jorge's passion for sustainability and ESG aligns closely with Moderna's vision to make corporate responsibility a critical part of who we are and what we do," Bancel said in the recent announcement.
And Gomez stated that it is a "privilege" for him to join an organization focused on developing transformative medicines to address major public healthcare challenges globally.
